@Sector You are finally partially correct …you spotted that I had omitted the word “twice weekly” from the summary on dosing for Temcell …nothing to do with Maths ! I showed the correct information from the original documentation …It was a simple faux pas. Now please correct your absurd assumption on margins for CLBP. Do you now accept that huge margins can be made from the CLBP treatment assuming even modest pricing of say $10,000?
Can you comment on the genotype of your universal donor for Cymerus ?
Do you know what differentiation there is between the surface receptors of your cells compared to ours ?
https://www.researchgate.net/publication/228668808_Mesenchymal_Stem_Cells_and_Their_Cell_Surface_Receptors
If you don’t …how on earth can you say, Cynata does not breach Mesoblasts patents relating to lineage or progeny even if you use MSA’s to begin with .
How long do you think it will take to gain FDA approval for your therapy…etc etc.
Perhaps its best if you toddle off !
Best
OP
- Forums
- ASX - By Stock
- Ann: MSB Presents at Edison Group Global Healthcare Conference
@Sector You are finally partially correct …you spotted that I...
-
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27197 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 43578 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 31763 | 1.100 |
2 | 33264 | 1.090 |
2 | 18897 | 1.085 |
2 | 18926 | 1.080 |
1 | 18000 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 23400 | 3 |
1.135 | 1090 | 1 |
1.140 | 65000 | 4 |
1.145 | 64500 | 3 |
1.150 | 92314 | 9 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |